Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Multiple Myeloma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 3Immunoglobulin Light-chain Amyloidosis 3Burkitt Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intraocular Lymphoma 1Hypersensitivity 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × dexamethasone 21-phosphate × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Active not recruiting
83 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Terminated
1 enrolled 7 charts
LymphoidOther hematologic neoplasm

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡